• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·ZENOTECH.BO
Share

Zenotech Laboratories Limited Stocks

₹ 41.05Last Updated 21.10.2026

Issuer Rating

2/7
Performance

Poor

Risk

Considerable

Recommendation

Sell

Market Cap

₹ 27.67M

₹ 41.05
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Zenotech Laboratories Ltd. is a pharmaceutical company specializing in the development, manufacturing, and commercialization of various medical products. Notably, its production activities include granulocyte-colony stimulating factor (GCSF) and granulocyte-macrophage colony-stimulating factor (GMCSF). The company's range of injectable offerings is strategically targeted at niche therapeutic areas such as oncology (cancer treatment) and anesthesiology. Founded on June 15, 1989, Zenotech Laboratories Ltd. maintains its headquarters in Hyderabad, India.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is overvalued on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

22.10.2026 17:05

Investors seeking safe havens have driven the valuations of "toothpaste" stocks above those of the tech sector

22.10.2026 16:35

Dividends, Gold, ETFs: Wall Street Outlines 5 Steps to Protect Your Portfolio from AI Risks

22.10.2026 16:35

Nebius Secured a $3.5 Billion Credit Line Amid a Sell-Off in AI-Sector Stocks

22.10.2026 15:47

AI Needs Energy and Power: 3 Stocks from Griffin's Portfolio with Growth Potential of Up to 400%

22.10.2026 15:25

Morning in New York: Tech Giants Wake Up the "Bears"

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026